FDA Accepts sNDA for Avatrombopag in ITP

November 8, 2018 – The FDA has accepted a supplemental new drug application (sNDA) for review for avatrombopag as a treatment for patients with chronic immune thrombocytopenia (ITP) who have had an inadequate response to prior treatment, according to Dova Pharmaceuticals, the developer of the second-generation, oral thrombopoietin receptor agonist. The application for avatrombopag was based on findings from the phase III Amendment 02 trial, which met … (leggi tutto)